“The FDA continues to make safe and potentially useful treatments for COVID-19 available as quickly as possible to help patients,” said FDA Commissioner Stephen Hahn. “The data supporting today’s action is encouraging. Data shows that this treatment has the potential to help even more hospital patients suffering the effects of this devastating virus.
“We are working with drug developers to conduct randomized clinical trials to further study the safety and effectiveness of a number of potential therapies against COVID-19,” he added.
The FDA said in its statement that it had determined it was “reasonable to believe” that remdesivir could be effective in treating suspected or confirmed cases of coronavirus in all hospitalized adults and children.
Studies have suggested that remdesivir is not a panacea for the coronavirus, with data from the New England Journal of Medicine showing that it alone does not cure patients with severe symptoms of COVID-19, although he helped patients recover faster than these. who did not receive the drug.
The Trump administration has put everything on the drug, buying up the entire global supply of antiviral drugs early on.
“It seems to be an approval model without science, without data, without evidence,” said Eric Topol, vice president of research at Scripps Research in La Jolla, Calif., And national expert on the use of data in medical research. United States today.
The FDA first cleared the use of remdesivir in hospitalized patients who needed oxygen but were not sick enough to require ventilation.